Who Will Be The First To Get A Psychedelic Drug Through The FDA To Commercialization?Psyched Wellness Is Laser Focused On Bringing Truly Differentiated Mushroom Products To MarketAtai Life Sciences: The Next Unicorn Of The Psychedelics SectorATAI Life Sciences Announces Closing of $125 Million Series C Financing RoundRritual Mushrooms Is Pioneering The Future Of Functional FoodsMindMed’s Drug Delivery Business Is One That Psychedelic Sector Investors Need To Be WatchingPure Extracts Technologies Corporate UpdateNova Mentis Life Science Announces Receipt of Pilz Shareholder ApprovalField Trip Health Ltd. Announces Expansion to The Netherlands and Launch of Proprietary Truffle ProgramPsyched Wellness Ltd. Announces Insider Buying and Option Grant to Professor NuttMindMed Receives Approval of Protocol Design to Evaluate Microdoses of LSD For Adult ADHD In Phase 2a Clinical Trial froTryp Appoints Dr. Jim Gilligan, PhD, MBIS, as President and Chief Scientific OfficerHavn Life Announces Launch of a Range of Natural Health ProductsCybin Corp. Will Make Its Debut Today On The NEO Under The Symbol “CYBN”Tryp Therapeutics Has “The Right Stuff” To Bring Psychedelic Therapies Through To CommercializationMindset Pharma Closes Ontario Brain Institute Funding and Announces Private Placement OfferingNuminus Wellness Is Executing Flawlessly On Their B2B Strategy via Numinus BiosciencesEntheon Biomedical Corp. (formerly MPV Exploration Inc.) Announces Completion of Amalgamation and Final Approval from thCybin Completes Reverse Take-Over TransactionThe Psychedelic Sector Is Getting A Major Momentum Boost Post U.S. Election

Technical420 Site Search

Returned 14 result(s).

Psyched Wellness Is Laser Focused On Bringing Truly Differentiated Mushroom Products To Market

After the results of the 2020 general election in the US were announced, the market became aware of two key trends. The first trend is related to positive legislation for the cannabis industry as it relates to the number of states that have legalized medical and recreational cannabis. The second…

Atai Life Sciences: The Next Unicorn Of The Psychedelics Sector

ATAI Life Sciences is considered to be a leading player in the psychedelic therapy sector after it closed a $125 million funding round that included a handful of strategic investors. We believe the size of the raise and the types of the investors that were involved with the financing add…

Numinus Wellness Is Executing Flawlessly On Their B2B Strategy via Numinus Biosciences

Last month, we issued an update on Numinus Wellness Inc. (TSXV: NUMI) and felt the need to provide an update on the business after it reported a major milestone.  Numinus announced that they have harvested the first legal flush of psilocybe mushrooms in Canada by a public company, out of…

MindMed Files Final Prospectus In Connection With Bought Deal Equity Financing

Mind Medicine (MindMed) Inc. (NEO: MMED) (OTCQB: MMEDF) is pleased to announce that further to its previously announced offering, it has filed a final short form prospectus with the securities commissions or similar authorities in each province of Canada, other than Québec. Pursuant to the underwriting agreement with Canaccord Genuity…

Numinus First Canadian Public Company to Complete Legal Harvest of Psilocybe Mushrooms

Numinus Wellness Inc. (TSXV: NUMI), a company creating an ecosystem of health solutions centred on developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies, has harvested the first legal flush of Psilocybe mushrooms in Canada by a public company under its Health Canada-issued Controlled Drugs and Substances Dealer's Licence. This news…

Wake Network Is Laser Focused On Advancing Fungi-Based Medicine Through Cutting Edge Technology and Clinical Research

A few months ago, we highlighted Wake Network as a psychedelic therapy company that we consider to be a leading play on an emerging industry and want to provide an update on the opportunity. Wake Network is laser focused on advancing fungi and plant-based medicine by leveraging clinical research, wellness…

MindMed Announces $25 Million Bought Deal Public Offering

Mind Medicine (MindMed) Inc. (NEO: MMED) (OTCQB: MMEDF) ("MindMed" or the "Company"), the leading neuro-pharmaceutical company for psychedelic inspired medicines, is pleased to announce that it has entered into an agreement with Canaccord Genuity Corp. (the "Lead Underwriter") pursuant to which the Lead Underwriter has agreed, on behalf of a…

3 Psychedelic Stocks With The Highest Chance Of Successfully Bringing A Psychedelic Therapy To Market

One of the most exciting growth stories in the biotech sector relates to the studies on psychedelic substances. The companies that focus on this vertical are working to develop treatments for mental illness. We are bullish on this opportunity due to the size of the total addressable market (TAM). Although…

Cybin Corp. Is A Best In Class Psychedelics Company When Compared To Industry Bellwether Compass Pathways

Last week, Compass Pathways (CMPS) commenced trading on the Nasdaq and became the first psychedelic drug company to go public on a major U.S. stock exchange. When Compass filed to go public, the deal generated substantially more interest from investors than expected. As a result, the psychedelic therapy company upsized…

Mind Medicine Inc. Announces Q2 2020 Financial Results

Mind Medicine (MindMed) Inc. (NEO: MMED OTCQB: MMEDF), the leading psychedelic pharmaceutical company, has announced its second quarter financial results for the three and six months ended June 30, 2020. Complete financial statements along with related management discussion and analysis can be found in the System for Electronic Document Analysis and…

Older Posts »

Search Again

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.
Subscribe
SUBSCRIBE NOW
close-link